H.R.1810 - Tom Lantos Pulmonary Hypertension Research and Education Act of 2011112th Congress (2011-2012)
|Sponsor:||Rep. Brady, Kevin [R-TX-8] (Introduced 05/10/2011)|
|Committees:||House - Energy and Commerce|
|Latest Action:||House - 05/13/2011 Referred to the Subcommittee on Health. (All Actions)|
This bill has the status Introduced
Here are the steps for Status of Legislation:
Summary: H.R.1810 — 112th Congress (2011-2012)All Information (Except Text)
Introduced in House (05/10/2011)
Tom Lantos Pulmonary Hypertension Research and Education Act of 2011 - Expresses the sense of Congress that: (1) the Secretary of Health and Human Services (HHS), acting through the Director of the National Institutes of Health (NIH) and the Director of the National Heart, Lung, and Blood Institute, should continue aggressive work on pulmonary hypertension; and (2) the Director of the Institute should continue research to expand the understanding of the causes of, and to find a cure for, pulmonary hypertension.
Requires inclusion of information on the status of pulmonary hypertension research at NIH in biennial reports to Congress.
Requires the Secretary, acting through the Director of the Centers for Disease Control and Prevention (CDC), to carry out an educational campaign to increase public awareness of pulmonary hypertension, which may include information on pulmonary hypertension and its symptoms, the incidence and prevalence of pulmonary hypertension, diseases and conditions that can lead to pulmonary hypertension as a secondary diagnosis, the importance of early diagnosis, and the availability of a range of treatment options.
Requires the Secretary, acting through the Administrator of the Health Resources and Services Administration (HRSA) and the Director of CDC, to carry out an educational campaign to increase awareness of pulmonary hypertension among health care providers, which may include information on: (1) the symptoms of pulmonary hypertension, (2) the importance of early diagnosis, (3) current diagnostic criteria, and (4) Food and Drug Administration (FDA)-approved therapies for the disease. Requires such campaign to target health care providers, including cardiologists, pulmonologists, rheumatologists, primary care physicians, pediatricians, and nurse practitioners.